TY - JOUR
T1 - Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance
T2 - data from the PRIAS–JAPAN study
AU - Tohi, Yoichiro
AU - Ishikawa, Ryou
AU - Kato, Takuma
AU - Miyakawa, Jimpei
AU - Matsumoto, Ryuji
AU - Mori, Keiichiro
AU - Mitsuzuka, Koji
AU - Inokuchi, Junichi
AU - Matsumura, Masafumi
AU - Shiga, Kenichiro
AU - Naito, Hirohito
AU - Kohjimoto, Yasuo
AU - Kawamura, Norihiko
AU - Inoue, Masaharu
AU - Kinoshita, Hidefumi
AU - Hashimoto, Kohei
AU - Goto, Keisuke
AU - Haba, Reiji
AU - Kakehi, Yoshiyuki
AU - Sugimoto, Mikio
N1 - Funding Information:
We would like to extend our thanks to Dr. Shintaro Narita, Dr. Wataru Obara, Dr. Mitsugu Kanehira, Dr. Kazuo Nishimura, Dr. Norio Nonomura, Dr. Koji Hatano, Dr. Kaneki Yasuda, Dr. Masatoshi Eto, Dr. Kenichi Tabata, Dr. Hideyasu Tsumura, Dr. Hiroshi Okuno, Dr. Takayoshi Miura, Dr. Shusuke Akamatsu, Dr. Osamu Ukimura, Dr. Takumi Shiroishi, Dr. Hiroshi Fukuhara, Dr. Naoki Ninomiya, Dr. Tomomi Kamba, Dr. Yoji Murakami, Dr. Yasuo Yamamoto, Dr. Tadashi Murata, Dr. Koji Inoue, Dr. Kazuhiro Suzuki, Dr. Yoshiyuki Miyazawa, Dr. Yukio Kageyama, Dr. Naoya Masumori, Dr. Takahiro Kimura, Dr. Katsuyoshi Hashine, Dr. Tomohiko Ichikawa, Dr. Shinichi Sakamoto, Dr. Nobuyoshi Takeuchi, Dr. Ayumi Fujimoto, Dr. Yukio Naya, Dr. Satoko Kojima, Dr. Akira Miyajima, Dr. Masahiro Nitta, Dr. Haruki Kume, Dr. Koichiro Akakura, Dr. Hiroyoshi Suzuki, Dr. Naoto Kamiya, Dr. Hiro-omi Kanayama, Dr. Yoshito Kusuhara, Dr. Yasuyoshi Miyata, Dr. Hiroki Kurata, Dr. Toshiki Tanikawa, Dr. Toshihiro Saito, Dr. Yoshihiko Tomita, Dr. Fumio Ishizaki, Dr. Takayuki Sugiyama, Dr. Hideaki Miyake, Dr. Akira Yokomizo, Dr. Nobuyuki Hinata, Dr. Takashige Abe, Dr. Satoru Maruyama, Dr. Toshiyuki Kamoto, Dr. Naoki Terada, Dr. Norihiko Tsuchiya, Dr. Hidenori Kanno, Dr. Hiroaki Matsumoto, Dr. Seiichi Saito, Dr. Ryu Kimura, Dr. Isao Hara, Dr. Hiromi Hirama, and the PRIAS–JAPAN secretary, Akiko Mori, for their great contribution to this study.
Publisher Copyright:
© 2022, The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
PY - 2023/2
Y1 - 2023/2
N2 - Background: Among early stage prostate cancer patients, intraductal carcinoma of the prostate (IDC-P) and invasive cribriform are key prognostic factors; however, their presence and clinical significance following active surveillance (AS) are unknown. In men who opted for AS, we aimed to examine the presence and impact of IDC-P or cribriform, utilizing radical prostatectomy (RP) specimens. Methods: We re-reviewed 137 RP specimens available in the PRIAS–JAPAN prospective cohort between January 2010 and September 2020. We assessed the presence of IDC-P or cribriform, and compared the patients’ characteristics and prostate-specific antigen (PSA) recurrence-free survival after RP between groups with and without IDC-P or cribriform. In addition, we examined the predictive factors associated with IDC-P or cribriform. Results: The percentage of patients with IDC-P or cribriform presence was 34.3% (47 patients). IDC-P or cribriform pattern was more abundant in the higher Gleason grade group in RP specimens (P < 0.001). The rates of PSA recurrence-free survival were significantly lower in the IDC-P or cribriform groups than in those without them (log rank P = 0.0211). There was no association between IDC-P or cribriform on RP with the Prostate Imaging-Reporting and Data System (PI-RADS) 4,5 score on magnetic resonance imaging (MRI) before RP even with adjustments for other covariates (OR, 1.43; 95% confidence interval [CI] 0.511–3.980, P = 0.497). Conclusions: IDC-P or cribriform comprised approximately one-third of all RP specimens in men who underwent RP following AS, confirming their prognostic significance.
AB - Background: Among early stage prostate cancer patients, intraductal carcinoma of the prostate (IDC-P) and invasive cribriform are key prognostic factors; however, their presence and clinical significance following active surveillance (AS) are unknown. In men who opted for AS, we aimed to examine the presence and impact of IDC-P or cribriform, utilizing radical prostatectomy (RP) specimens. Methods: We re-reviewed 137 RP specimens available in the PRIAS–JAPAN prospective cohort between January 2010 and September 2020. We assessed the presence of IDC-P or cribriform, and compared the patients’ characteristics and prostate-specific antigen (PSA) recurrence-free survival after RP between groups with and without IDC-P or cribriform. In addition, we examined the predictive factors associated with IDC-P or cribriform. Results: The percentage of patients with IDC-P or cribriform presence was 34.3% (47 patients). IDC-P or cribriform pattern was more abundant in the higher Gleason grade group in RP specimens (P < 0.001). The rates of PSA recurrence-free survival were significantly lower in the IDC-P or cribriform groups than in those without them (log rank P = 0.0211). There was no association between IDC-P or cribriform on RP with the Prostate Imaging-Reporting and Data System (PI-RADS) 4,5 score on magnetic resonance imaging (MRI) before RP even with adjustments for other covariates (OR, 1.43; 95% confidence interval [CI] 0.511–3.980, P = 0.497). Conclusions: IDC-P or cribriform comprised approximately one-third of all RP specimens in men who underwent RP following AS, confirming their prognostic significance.
UR - http://www.scopus.com/inward/record.url?scp=85143418073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143418073&partnerID=8YFLogxK
U2 - 10.1007/s10147-022-02277-8
DO - 10.1007/s10147-022-02277-8
M3 - Article
C2 - 36472710
AN - SCOPUS:85143418073
SN - 1341-9625
VL - 28
SP - 299
EP - 305
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 2
ER -